IGF‑1 LR3 is a synthetic analog of human IGF‑1, featuring an arginine substitution at position 3 and an additional 13 amino acids on the N‑terminus, extending its size to 83 amino acids. These modifications significantly increase its potency—around threefold—while prolonging its half-life to approximately 20–30 hours due to reduced affinity for IGF-binding proteins . In preclinical rodent studies, IGF‑1 LR3 effectively stimulates skeletal muscle protein synthesis, promoting hypertrophy and regeneration, and activates satellite cell proliferation to support repair . In food-restricted rats, continuous infusion of IGF‑1 LR3 helped maintain body weight and nitrogen retention, though effects on muscle preservation varied depending on age and nutritional status . Hemodynamic investigations in anesthetized rats revealed that IGF‑1 LR3 greatly enhances blood flow to skeletal muscle—up to a 308% increase—while significantly reducing vascular resistance, suggesting potent effects on circulation in target tissues . Additional studies have explored its neuroprotective potential in murine models of Alzheimer’s disease, where intranasal administration of IGF‑1 LR3 improved amyloid plaque remodeling in the cortex, though without preventing cognitive decline.

Peptides are available for research purposes only.
Please review and adhere to our Terms and Conditions before ordering.